Author |
Topic: drap (Read 272 times) |
|
drap
New Board Newbie
I love YaBB 1G - SP1!
Posts: 35
|
has anybody heard anything about using vioxx for CH.
drap
|
|
 IP Logged |
|
|
|
pubgirl
Guest
|
Sorry Drap, have never heard of anyone taking it for anything other than menstrual pain or arthritis and can't imagine why any doctor would think a non steroidal anti-inflammatory drug would be one of choice for CH 
Wendy
|
|
IP Logged |
|
|
|
Tom
New Board Veteran
I love YaBB 1G - SP1!
Gender: 
Posts: 208
|
 |
Re: drap
« Reply #2 on: Apr 5th, 2004, 4:37pm » |
 Quote  Modify
|
VIOXX® = rofecoxib = one of the NSAID
The mechanism of action of VIOXX is believed to be due to inhibition of prostaglandin synthesis, via inhibition of cyclooxygenase- 2 (COX- 2).
Another drug from the same chemical group is Celebrex® = celecoxib, sometimes used successfully in the treatment of PPH/CPH as (probably better tolerated) alternative to indomethacin.
Neither rofecoxib nor celecoxib or indomethacin help CH, but it's always worth to give one of them a try, in case it could be PPH or CPH.
Thomas
|
| « Last Edit: Apr 6th, 2004, 1:17pm by Tom » |
IP Logged |
Thomas/Munich
|
|
|
pubgirl
Guest
|
Thomas
Interesting about the use of prostaglandin inhibitors for PH, especially as quite a few people find indomethacin messes up their insides too badly. I shall log that one in my brain for the future.
I take a prostaglandin inhibitor (mefenamic acid) on a regular basis for a different problem, and I can confirm it certainly does absolutely nothing to help my clusters.
W
|
|
IP Logged |
|
|
|
floridian
Guest
|
At lower doses, vioxx decreases cox-2 but can increase nitric oxide production -- nitric oxide is one of the inflammatory mediators close to the pain in cluster headaches and too much NO is not good. At very high doses, vioxx decreases NO, but toxicity becomes a problem.
Tea flavonoids sponge up nitric oxide. Curcumin (from turmeric) also inhibits cox-2, nitric oxide, phospholipase, lipooxygenase, leukotrienes, thromboxane, prostaglandins, collagenase, elastase, hyaluronidase, monocyte chemoattractant protein-1 (MCP-1), interferon-inducible protein, tumor necrosis factor (TNF), and interleukin-12 (IL-12) .
Quote:J Pharmacol Exp Ther. 2003 Mar;304(3):1153-60.
Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation.
Niederberger E, Tegeder I, Schafer C, Seegel M, Grosch S, Geisslinger G.
Pharmazentrum frankfurt, Klinikum der Johann Wolfgang Goethe-Universitat Frankfurt, Frankfurt am Main, Germany. e.niederberger@em.uni-frankfurt.de
Rofecoxib is a selective cyclooxygenase (COX)-2 inhibitor approved for the treatment of pain and inflammation in rheumatoid and osteoarthritis. Daily doses between 12.5 and 50 mg were found to reduce pain and inflammation, however, without a clear dose-effect relationship. Interestingly, rofecoxib treatment is associated with an unexpected incidence of renal adverse events compared with other COX inhibitors. Here, the effects of rofecoxib on the transcription factors nuclear factor-kappaB (NF-kappaB) and activating protein-1 (AP-1) were analyzed to find out whether transcriptional changes might explain the lack of clear dose dependency and the occurrence of renal side effects. In vitro, rofecoxib dose dependently inhibited DNA binding capacity of NF-kappaB at doses of 10 to 100 microM, whereas the binding activity of AP-1 was considerably increased at 100 microM. In vivo, the anti-inflammatory effect of rofecoxib was equal at 1 and 10 mg/kg, whereas 50 mg/kg caused a significant further reduction of a zymosan-induced paw edema. This was associated with a clear decrease of inducible nitric oxide synthase (iNOS) protein expression in the spinal cord at this dose. At 1 and 10 mg/kg, however, iNOS was increased but COX-2 was decreased. Thus, the expression of proinflammatory proteins was similarly inconsistent as transcription factor regulation. In conclusion, the opposite effects of rofecoxib on AP-1 and NF-kappaB may explain the lack of clear dose dependency with rofecoxib in clinical studies or animal experiments. The effects on AP-1 may possibly affect renal sodium transport because certain renal sodium channels are regulated through AP-1. Transcription factor regulation might therefore influence both wanted and unwanted effects of rofecoxib.
|
|
|
| « Last Edit: Apr 6th, 2004, 8:43am by floridian » |
IP Logged |
|
|
|
|
|
|
Home
Help
Search
Members
Member Map
Login
Register
Reply
Notify of replies
Send Topic
Print
Remove
test rss